Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230789 · ClinicalTrials.gov registry record · Phase 4
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 417
- Enrollment target
NCT00230789 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 417 participants.
The verdict
NCT00230789, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 417 participants
- Enrollment target
Study Summary
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
Interventions
- DRUG Tolterodine ER 4 mg QD
- BEHAVIORAL OAB Patient Behavioral Training Material
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230789
The ClinicalTrials.gov registry entry for NCT00230789 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tolterodine ER 4 mg QD is the first listed.
NCT00230789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230789 about?
NCT00230789 is a clinical study titled "Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.". To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
What is the current status of trial NCT00230789?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 417 participants. The study started on 2005-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00230789?
The interventions under investigation include: Tolterodine ER 4 mg QD (DRUG), OAB Patient Behavioral Training Material (BEHAVIORAL).
Who is sponsoring clinical trial NCT00230789?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.